Interesting case series (n=3) from Emory of patients with pretreated HER2+ and HER2-low MBC with severe hepatic impairment tolerating well and deriving clinical benefit from dose-reduced T-DXd. https://www.sciencedirect.com/science/article/pii/S2666621924000590?via%3Dihub
Comments